Commonwealth of Pennsylvania Public School Empls Retrmt SYS Raises Stake in Inari Medical,

🌥️Trending News

The Commonwealth of Pennsylvania Public School Employees Retirement System recently announced that it has increased its stake in Inari Medical ($NASDAQ:NARI), Inc., a medical device company that focuses on the development of catheter-based products for the treatment of peripheral vascular and structural heart diseases. Inari Medical has developed several innovative products which are designed to provide minimally invasive treatment options for peripheral artery disease (PAD) and structural heart disease. The company’s flagship product, the FlowTriever™ thrombectomy system, is the first and only device cleared by the FDA to treat PAD. The FlowTriever™ is designed to rapidly restore blood flow to the leg using a single procedure, which can reduce the risk of amputation and improve quality of life for patients with PAD. In addition to the FlowTriever™, Inari Medical is also developing a suite of other catheter-based products for use in the treatment of structural heart disease.

The company’s next-generation NEXUS™ device is designed to be used in Transcatheter Aortic Valve Replacement (TAVR) procedures, which replace diseased heart valves without open-heart surgery. The Commonwealth of Pennsylvania Public School Employees Retirement System’s decision to increase its stake in Inari Medical reflects the company’s commitment to developing innovative treatments for vascular and structural heart disease. The increased investment will help to further support Inari Medical’s continued growth and development.

Market Price

On Monday, Commonwealth of Pennsylvania Public School Employees’ Retirement System (PSERS) reported that it had increased its stake in Inari Medical, Inc., a medical device company focused on minimally invasive treatments for vascular diseases. The stock opened at $58.7 and closed at $58.4, representing a 1.0% decrease from the previous closing price of $59.0. It is unclear what the exact size of the increase was, or why PSERS chose to invest in Inari Medical.

However, the increase in investment comes as a sign of confidence in Inari Medical’s future prospects. This is likely to be a positive development for Inari Medical, as it suggests that larger institutional investors are seeing potential in the company and are investing accordingly. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Inari Medical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Inari Medical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Inari Medical. More…

Key Ratios Snapshot

Some of the financial key ratios for Inari Medical are shown below. More…

Analysis

At GoodWhale, we conducted an analysis of INARI MEDICAL‘s fundamentals. We classified it as ‘gorilla’, indicating that it has achieved stable and high revenue or earning growth due to its strong competitive advantage. This makes INARI MEDICAL an attractive target for a wide range of investors, such as growth investors or value investors. In terms of its financials, INARI MEDICAL is strong in asset, growth, and profitability. However, it is weak in dividend. On the other hand, the health score of 6/10 indicates that INARI MEDICAL is likely to weather any crisis without the risk of bankruptcy. Overall, INARI MEDICAL stands out as a good investment for investors who are looking for high growth and stability. More…

Peers

Its competitors are OncoSil Medical Ltd, ShockWave Medical Inc, and Vycor Medical Inc.

– OncoSil Medical Ltd ($ASX:OSL)

OncoSil Medical Ltd is a medical device company that develops, manufactures and markets products for the treatment of cancer. The company has a market cap of 47.58M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to target and destroy cancer cells while sparing healthy tissue. The company’s lead product, OncoSil, is a radioactive silicone particle that is injected into solid tumors. OncoSil has been shown to be effective in the treatment of pancreatic, brain, and ovarian cancer.

– ShockWave Medical Inc ($NASDAQ:SWAV)

As of 2022, ShockWave Medical Inc has a market cap of 10.19B and a Return on Equity of 12.48%. The company is a medical device company that uses shockwave technology to treat cardiovascular diseases. The company’s products are sold in over 30 countries and are backed by over 100 patents.

– Vycor Medical Inc ($OTCPK:VYCO)

Vycor Medical Inc is a publicly traded company with a market capitalization of 3.1 million as of 2022. The company has a return on equity of 6.36%, which is relatively high compared to other companies in the same industry. Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the neurosurgery market. The company’s products are used by surgeons to treat conditions such as brain tumors, cerebral aneurysms, and skull-base tumors.

Summary

INARI Medical, Inc. has recently been the recipient of a substantial investment from the Commonwealth of Pennsylvania Public School Employees Retirement System. This is a major vote of confidence in the company’s business model and potential for future growth. Analysts have studied INARI’s financials and technology, concluding that the company has strong fundamentals and an attractive portfolio of products.

The current market conditions are also favorable for the company’s growth, and analysts believe that there is significant potential for strong returns in the near and medium term. Overall, INARI’s financial and business outlook is positive and investors should consider the potential for strong returns when considering an investment in this company.